CTRI/2019/01/017121已完成未知
A Prospective open randomized, parallel group clinical study to evaluate the efficacy and safety of topical treatment in the management of Hemorrhoids in adults.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Giellepi Spa
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects willing to give written informed consent.
- •2. Male or female subjects, between 18 years of age and 70 years age with a diagnosis of haemorrhoids (first or
- •second degree).
- •3. Except hemorrhoids (first or second degree), the subjects are judged to be in good general health,
- •based on medical history, physical examination.
- •4. If female of childbearing age, they should be willing to use an acceptable form of birth control
- •measure. They should be stable since last 3 months prior to baseline and throughout the study.
- •5. Subjects accepting to be on controlled and balanced diet (with exclusion of some foods including hot chili, pepper, chocolate, alcoholic drinks, fried foods). Tea and coffee will be restricted to not
- •more of 2 cups per day.
排除标准
- •1.Pregnant and lactating women and women in post-partum period of up to 6 weeks.
- •2. Subjects with a history of permanent anal prolapse and/or anal fistula
- •3. Subjects with associated anal fissures and/or infective anal pathology.
- •4. Subjects with previous history of surgery for anorectal disease (within 5 years) or any other
- •procedures (including but not limited to injection sclerotherapy, rubber band ligation,
- •photocoagulation, cryotherapy etc) within 2 years of enrolment into the trial.
- •5. Subjects who, in the opinion of the investigator, are mentally incapacitated such that informed
- •consent cannot be obtained.
- •6. Subjects with clinically significant co-morbid condition that in the opinion of the investigator
- •could affect the efficacy and safety outcome of the study.
- •7. Patients under treatment with other topical therapy for haemorrhoidal syndrome.
- •8. Subjects participating in any other clinical trial currently or if he/she has completed the trial
- •participation less than 3 months from screening for the current study.
- •9. Presence of disease states that could affect safety and efficacy evaluation, such as hepatic (e.g.,
- •cirrhosis with Child-Pugh Class B or C or MELD score > 9), renal (e.g., requiring dialysis), gastrointestinal (e.g., acute or chronic diverticulitis, irritable bowel syndrome with epigastric pain as a predominant symptom or active inflammatory bowel disease), hematologic, neurologic or brain disorders (e.g., strokes, and brain injury), psychiatric (e.g., bipolar disorder, severe active depression, severe active anxiety), or any other significant condition which, in the opinion of the Investigator, could confound or interfere with evaluation of efficacy, safety, or tolerability of the investigational drug, or prevent compliance with the study protocol.
- •10. Subjects unwilling to sign the inform consent document.
- •11. Any condition that in the opinion of the investigator does not justify the subjects inclusion for the
- •12. Known hypersensitivity to, or intolerance of, investigational product or any excipient.
研究者
相似试验
Unknown
不适用
A clinical trial of a cream to be applied locally for adult subjects with painful growth in the anal region.CTRI/2018/10/016046Giellepi Spa
进行中（未招募）
1 期
A study to evaluate the safety of stopping versus continuing anti TNF therapy in ulcerative colitis patients in remission, and to evaluate the safety and efficacy of restarting anti TNF therapy in patients with disease recurrencelcerative colitisMedDRA version: 19.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2016-001409-18-NOHelse More og Romsdal Hospital Trust
进行中（未招募）
1 期
Comparison of a 12 month vs. a short-term therapy with prasugrel in patients with acute heart attack undergoing coronary stentingEUCTR2013-001636-22-DEHospital of the University of Munich, Grosshadern2,600
进行中（未招募）
1 期
Comparison of a 12 month vs. a short-term therapy with prasugrel in patients with acute heart attack undergoing coronary stentingEUCTR2013-001636-22-PLHospital of the University of Munich, Grosshadern2,600
进行中（未招募）
1 期
Comparison of a 12 month vs. a short-term therapy with prasugrel in patients with acute heart attack undergoing coronary stentingTroponin positive acute coronary syndrome after successful percutaneous coronary intervention with an indication for a standard treatment of 12 month with prasugrelMedDRA version: 17.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersEUCTR2013-001636-22-HUHospital of the University of Munich, Grosshadern2,600